{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:11:19Z","timestamp":1786997479271,"version":"build-2736575974"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.thromres.2014.07.026","type":"journal-article","created":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T15:27:05Z","timestamp":1406129225000},"page":"643-647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["FondaKIDS II: Long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7603-6697","authenticated-orcid":false,"given":"Richard H.","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Michieli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Lira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.thromres.2014.07.026_bb0005","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1542\/peds.2009-0768","article-title":"Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007","volume":"124","author":"Raffini","year":"2009","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.thromres.2014.07.026_bb0010","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1586\/ecp.12.23","article-title":"Pharmacokinetic- and pharmacodynamic-based antithrombotic dosing recommendations in children","volume":"5","author":"Ko","year":"2012","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.thromres.2014.07.026_bb0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.thromres.2004.12.017","article-title":"Oral anticoagulation therapy in children","volume":"118","author":"Bonduel","year":"2006","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.thromres.2014.07.026_bb0020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2141.2010.08225.x","article-title":"Aspects of anticoagulation in children","volume":"150","author":"Payne","year":"2010","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.thromres.2014.07.026_bb0025","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1538-7836.2007.02624.x","article-title":"Once-daily enoxaparin in pediatric thromboembolism: a dose finding and pharmacodynamics\/pharmacokinetics study","volume":"5","author":"O'Brien","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 3","key":"10.1016\/j.thromres.2014.07.026_bb0030","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1007\/PL00014339","article-title":"The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases","volume":"158","author":"Nohe","year":"1999","journal-title":"Eur J Pediatr"},{"issue":"6","key":"10.1016\/j.thromres.2014.07.026_bb0035","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1160\/TH05-03-0215","article-title":"Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events","volume":"94","author":"Kuhle","year":"2005","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.thromres.2014.07.026_bb0040","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.thromres.2006.10.025","article-title":"The effects of heparin and low molecular weight heparins on bone","volume":"122","author":"Rajgopal","year":"2008","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.thromres.2014.07.026_bb0045","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/pbc.23011","article-title":"FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18years of age","volume":"57","author":"Young","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.thromres.2014.07.026_bb0050","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00223-002-2091-5","article-title":"Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts","volume":"73","author":"Matziolis","year":"2003","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"10.1016\/j.thromres.2014.07.026_bb0055","first-page":"13","article-title":"Fondaparinux-associated heparin-induced thrombocytopenia","volume":"25","author":"Burch","year":"2012","journal-title":"Proceedings"},{"issue":"1","key":"10.1016\/j.thromres.2014.07.026_bb0060","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1160\/TH07-04-0252","article-title":"Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia","volume":"99","author":"Lobo","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.07.026_bb0065","first-page":"542","article-title":"Use of argatroban and fondaparinux in a child with heparin-induced thrombocytopenia","volume":"42","author":"Young","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.thromres.2014.07.026_bb0070","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1182\/blood.V104.11.4072.4072","volume":"104","author":"Boshkov","year":"2004","journal-title":"Blood"},{"issue":"2 Suppl.","key":"10.1016\/j.thromres.2014.07.026_bb0075","doi-asserted-by":"crossref","first-page":"e737S","DOI":"10.1378\/chest.11-2308","article-title":"American College of Chest P. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Monagle","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.thromres.2014.07.026_bb0080","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1538-7933.2004.0584a.x","article-title":"Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activity","volume":"2","author":"Depasse","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.thromres.2014.07.026_bb0085","first-page":"155","article-title":"Monitoring plasma levels of factor Xa inhibitors: how, why and when? Expert review of hematology","volume":"6","author":"Samama","year":"2013"},{"issue":"6","key":"10.1016\/j.thromres.2014.07.026_bb0090","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/sj.bjp.0707447","article-title":"Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and children","volume":"153","author":"Nowak-Gottl","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"7","key":"10.1016\/j.thromres.2014.07.026_bb0095","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1055\/s-0031-1297173","article-title":"Safety and efficacy of low molecular weight heparins in children: a systematic review of the literature and meta-analysis of single-arm studies","volume":"37","author":"Bidlingmaier","year":"2011","journal-title":"Semin Thromb Hemost"},{"issue":"12","key":"10.1016\/j.thromres.2014.07.026_bb0100","first-page":"1701","article-title":"Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: an open-label pilot study of once-daily versus twice-daily enoxaparin administration","volume":"91","author":"Schobess","year":"2006","journal-title":"Haematologica"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814004034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814004034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T10:19:43Z","timestamp":1598091583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384814004034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0049384814004034"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2014.07.026","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FondaKIDS II: Long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2014.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}